AUSTIN, Texas & TORONTO--(BUSINESS WIRE)--Triumvira Immunologics, Inc., a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointment of Scott Smith to the Board of Directors.
“We are thrilled to welcome Scott to the Triumvira Board of Directors,” said President and CEO of Triumvira Immunologics, Dr. Paul Lammers. “Scott's leadership experience in immunology and oncology, together with his commercial operations expertise, will be instrumental as we build our company and work to bring new treatments to patients in need through our proprietary T Cell-Antigen Coupler (TAC) technology.”
In his most recent role at Celgene, Mr. Smith was the President and Chief Operating Officer where he was responsible for all key functions including Oncology Franchise Commercial Operations, Inflammation & Immunology Franchise Commercial Operations, Clinical Development, Regulatory Affairs and Manufacturing. Prior to that, Smith held the role of President, Inflammation & Immunology/Executive Vice President at Celgene and lead the charge in taking its lead candidate through proof of concept, clinical development, approval and global commercialization and established Inflammation & Immunology as a standalone franchise at Celgene. He was Vice President, Global Marketing before moving into these executive roles at Celgene.
“I am excited to join the Triumvira Board of Directors and be part of its efforts to change lives using its novel TAC technology,” said Smith. “There is a real need within the field of cellular immuno-therapy for an approach that optimizes anti-tumor activity, but also controls toxicity.”
Prior to his time at Celgene, Mr. Smith held various positions, including Biovail Pharmaceuticals and Pharmacia (now a Pfizer company).
About Triumvira Immunologics
Triumvira Immunologics, Inc. is an immuno-oncology company, developing a novel platform for engineering T cells to attack both liquid and solid tumors. Triumvira’s proprietary T Cell-Antigen Coupler (TAC) co-opts the natural T Cell receptor biology and functions. This approach operates through the native T cell receptor, in turn optimizing selectivity and signaling, and has demonstrated superiority over CAR-T in pre-clinical studies. Led by a management team with decades of drug development expertise, Triumvira’s pipeline includes multiple oncology trials slated to enter the clinic in 2019.
